Enfortumab Vedotin–related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the Literature

• Published in: European urology open science (Online) Vol. 49; pp. 100 - 103
• Main Authors: Vlachou, Evangelia, Matoso, Andres, McConkey, David, Jing, Yuezhou, Johnson, Burles Avner, Hahn, Noah M., Hoffman-Censits, Jean
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.03.2023; Elsevier
• Subjects: Advanced urothelial cancer; African American; Bladder cancer; Brief Correspondence; Cutaneous adverse events; Disease response; Enfortumab vedotin; Metastatic urothelial cancer; Skin toxicity; Upper tract urothelial cancer; Urothelial cancer; Urothelial cancer; Enfortumab vedotin; Metastatic urothelial cancer; Skin toxicity; Upper tract urothelial cancer; Cutaneous adverse events; Bladder cancer; Disease response; Advanced urothelial cancer; African American

Enfortumab vedotin (EV) is an antibody-drug conjugate approved for the treatment of refractory advanced urothelial cancer. Cutaneous toxicity is well described but has not been correlated with response. In this retrospective single-center study, data from patients treated with more than one dose of...